{"nctId":"NCT03048747","briefTitle":"A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH","startDateStruct":{"date":"2017-03-02","type":"ACTUAL"},"conditions":["Syndrome of Inappropriate Antidiuretic Hormone Secretion"],"count":16,"armGroups":[{"label":"Tolvaptan","type":"EXPERIMENTAL","interventionNames":["Drug: Tolvaptan Oral Tablet"]}],"interventions":[{"name":"Tolvaptan Oral Tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a definite diagnosis of SIADH in reference to \"Diagnostic and Treatment Manual of the Hypersecretion of Vasopressin (SIADH), Revised in 2011\"\n* Subjects who have been on fluid restriction for at least 7 consecutive days at the time of informed consent and who are showing no improvement of hyponatremia at the time of the screening examination\n\nExclusion Criteria:\n\n* Subjects who have transient hyponatremia induced by drug administration\n* Subjects who are unable to sense thirst or who have difficulty with fluid intake\n* Subjects with urinary tract obstruction\n* Subjects who have participated in any other clinical trial within 30 days prior to informed consent\n* Subjects with serum sodium concentration of \\<120 mEq/L associated with neurologic impairment, including apathy, confusion, or seizures","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration","description":"The percentage of subjects with normalized serum sodium concentration, defined as â‰¥135 mEq/L, on the day after final IMP administration will be calculated versus the number of subjects with serum sodium concentration of \\<135 mEq/L at baseline on Day 1 of the treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Serum Sodium Concentration","description":"The mean and standard error of measured values for serum sodium concentration on the day of fixing the maintenance dose and on the day after final IMP administration were calculated.\n\nThe day of fixing the maintenance dose: Day2, Day3, Day4, Day5, Day7, Day14, and Day21","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"3.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"4.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":"3.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.4","spread":"6.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":"4.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":16},"commonTop":["Thirst","Decreased appetite","Neutropenia","Constipation","Nausea"]}}}